The positive biomarker data for BGE-102 supports its potential as a best-in-class oral NLRP3 inhibitor, with upcoming Phase 2a readouts in 2026 serving as key catalysts. The expanded indication into DME diversifies clinical risk. While fundamentals remain pre-revenue and loss-making, the strong cash position de-risks near-term execution. Traders should monitor Phase 2a initiation and data timelines as potential upside triggers.
BIOA drugs
BIOA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 24 $16.11entry
- T+1 · 8mo ago +1.86%α +1.30% · $16.41
- T+5 · 8mo ago +8.57%α +8.99% · $17.49
- T+20 · 7mo ago +13.97%α +5.07% · $18.36
- T+60 · 5mo ago +28.93%α +14.60% · $20.77
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BioAge Labs reported its full-year 2025 financial results alongside key clinical and corporate updates, including positive Phase 1 data for its NLRP3 inhibitor BGE-102, expansion into ophthalmology, and completion of a $132.3 million follow-on offering. The company now has $285.1 million in cash, funding operations through 2029. While collaboration revenue rose to $9.0 million, R&D and G&A expenses increased, resulting in a net loss of $80.6 million.
Key Financial Metrics
Key Facts
- Positive interim Phase 1 data for BGE-102 showed 86% median reduction in hsCRP, 58% in IL-6, and 30% in fibrinogen in obese patients with elevated inflammation.
- Phase 2a proof-of-concept trial in cardiovascular risk to initiate in 1H 2026; data expected in 2H 2026.
- BGE-102 program expanded into diabetic macular edema (DME), with Phase 1b/2a trial planned for mid-2026.
- Completed upsized follow-on offering raising $132.3 million in gross proceeds, strengthening cash position.
- Cash, cash equivalents, and marketable securities totaled $285.1 million as of December 31, 2025, sufficient to fund operations through 2029.
- Collaboration revenue was $9.0 million in 2025 (vs. $0 in 2024), driven by the Novartis partnership.
- R&D expenses rose to $73.9 million (from $59.0 million in 2024), primarily due to BGE-102 and APJ agonist programs, partially offset by termination of azelaprag.
- Net loss was $80.6 million in 2025 ($2.24 per share), compared to $71.1 million ($6.63 per share) in 2024.
Financial Impact
Revenue increased by $9.0 million due to Novartis collaboration, but R&D and G&A expenses rose by $14.9M and $8.6M respectively, leading to a larger net loss. However, the $132.3M capital raise significantly extends runway.
Risk Factors
- Clinical development risk: BGE-102 is still in early stages; Phase 2a data may not confirm efficacy.
- Dilution from the follow-on offering: 6.8M shares issued, increasing share count by ~18%.
- High cash burn: Despite extended runway, R&D spending is accelerating, and future financings may be needed before commercialization.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3261303 |
Track record
11 reports on BIOA
2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +13.00% at T+60 after the Apr 21, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $5.50 Now $5.24 −4.73% settles Nov 23
- Nov 5, 202610d ago 8-K Neutral 4/10 No price data
- Nov 5, 202610d ago Press Release Neutral 4/10 Entry $5.34 to $5.55 Now $5.24 −1.87% ▲ +3.93% +1.34% vs SPY
- Jun 16, 202621w ago Press Release Neutral 3/10 Entry $20.49 to $22.32 Now $5.24 −74.43% ▲ +8.93% +11.16% vs SPY
- May 8, 202627w ago 8-K Bullish 7/10 Entry $17.99 to $18.72 Now $5.24 −70.87% ▲ +4.03% +2.57% vs SPY
- Apr 21, 202629w ago DEFA14A Neutral 3/10 Entry $18.36 to $17.14 Now $5.24 −71.46% ▼ −6.64% −6.70% vs SPY
- Apr 21, 202629w ago Press Release Bullish 8/10 Entry $19.61 to $17.44 Now $5.24 −73.28% ▼ −11.07% −12.15% vs SPY
- Apr 1, 202632w ago 144 Neutral 3/10 Entry $17.73 to $17.79 Now $5.24 −70.45% ▲ +0.34% −3.43% vs SPY
- Mar 24, 202633w ago Press Release Mixed 6/10 Viewing Entry $16.11 to $17.49 Now $5.24 −67.47% ▲ +8.57% +8.99% vs SPY
- Mar 2, 202637w ago Court Ruling Bullish 7/10 Entry $20.46 to $20.97 Now $5.24 −74.39% ▲ +2.49% +2.96% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers